

SHAREHOLDERS AND INVESTORS COMMUNICATION POLICY

This policy sets out the standards and requirements of the Company in relation to communicating with its shareholders and investors.

1. SHAREHOLDERS COMMUNICATION

Direct engagement with shareholders provides better appreciation of the Company's objectives, quality of its management and challenges, while also making the Company aware of the expectations and concerns of its shareholders. In this regard, the Company has established the following communication channels with its shareholders:

(A) ANNUAL GENERAL MEETING (AGM)

- (i) The Company regards the AGM as an important event in the corporate calendar of which all Directors and key senior executives should attend.
- (ii) The Company regards the AGM as an important forum for dialogue with shareholders and aims to ensure that the AGM provides an important opportunity for effective communication with and constructive feedback from the Company's shareholders.
- (iii) The Chairman encourages active participation by the shareholders during the AGM.
- (iv) In addition to the normal agenda for the AGM, the Board presents the progress and performance of the business as contained in the Annual Report and provides opportunities for shareholders to raise questions pertaining to the business activities of the Group. Shareholders who are unable to attend are allowed to appoint proxies to attend and vote on their behalf. Where necessary, the Chairman / the Group Managing Director / Chief Executive Officer will undertake to provide written answers to any significant questions that cannot be readily answered at the meeting.

(v) A press conference will also be held after each general meeting. At this press conference the Chairman or the Group Managing Director / Chief Executive Officer will provide an insight of the Company's performance for the year, prospects and any specific events within the guidelines of the Company's Corporate Disclosure Policy.

(B) EXTRAORDINARY GENERAL MEETINGS (EGM) WILL BE HELD AS AND WHEN REQUIRED.

The Directors will consider requisitions by shareholders to convene EGM or any other urgent matters requiring immediate attention of the Company.

(C) ANNUAL REPORT

The Directors believe that an important channel to reach shareholders and investors is through the Annual Report. Besides including comprehensive financial performance and information on business activities, the Group strives to improve the contents of the Annual Report in line with the developments in corporate governance practices.

The Company's Annual Report can be obtained by accessing the Company's website at www.duopharmabiotech.com

(D) COMPANY'S WEBSITE

The Company also maintains a website at www.duopharmabiotech.com which can be accessed by shareholders to keep abreast with the Company's development. The Board ensures the timely release of financial results on a quarterly basis to provide shareholders with an overview of the Company's performance and operations in addition to the various announcements or press releases made during the year. The shareholders can also leave their queries / feedback on the Company's website.

The Company's website provides easy access to corporate information pertaining to the Company and its activities. The website is continuously updated.

2. INVESTORS RELATION

The Group also holds briefings / dialogues with institutional investors, fund managers, analysts and research houses. Analysts and investors are briefed as required, in relation to major corporate exercises and pertinent issues within the disclosure requirements of Bursa Malaysia.

3. DISCLOSURE OF INFORMATION

While the Group endeavours to provide as much information as possible to its shareholders and stakeholders, it must also be wary of the legal and regulatory framework governing the release of material and price-sensitive information. All corporate disclosures take into account the prevailing legislative restrictions and requirements as well as the investors need for timely release of price-sensitive information such as financial performance results and statements, material acquisitions, significant corporate proposals as well as other significant corporate events.

In all circumstances, the Group is cautious not to provide undisclosed material information about the Group and continually stresses on the importance of timely and equal dissemination of information to shareholders and stakeholders.

4. SHAREHOLDER PRIVACY

The Company recognizes the importance of shareholders' privacy and will not disclose shareholders' information without their consent unless required by law.

5. ACCESS TO POLICY

This policy will be available for viewing on the Company's website.

6. REVIEW OF THIS POLICY

This policy is subject to regular review by the Board and will be amended (as appropriate) to reflect current best practice in communications with shareholders.

7. COMPANY CONTACTS

(A) Shareholdings

Tricor Investor & Issuing House Services Sdn Bhd
Unit 32-01, Level 32, Tower A,
Vertical Business Suite, Avenue 3,
Bangsar South, No. 8, Jalan Kerinchi,
59200 Kuala Lumpur, Malaysia

Tel: 03-2783 9299

Fax: 03-2783 9222

(B) Corporate Governance

Company Secretary
Duopharma Biotech Berhad
(formerly known as CCM Duopharma Biotech Berhad)
Suite 18.06, Level 18, Kenanga International,
No. 26, Jalan Tun Razak,
50250 Kuala Lumpur.

Tel: 03-2162 0218

Fax: 03-2161 0451

Email: cs@duopharmabiotech.com